Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome

Postremission treatment is crucial to prevent relapse in acute myeloid leukemia (AML). High-dose cytarabine delivered every 12 hours on days 1, 3, and 5 (HDAC-135) is the standard of care for younger adult patients with AML. Although this standard has been unsuccessfully challenged by other treatmen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Dumas, Pierre-Yves, Bertoli, Sarah, Bérard, Emilie, Leguay, Thibaut, Tavitian, Suzanne, Galtier, Jean, Alric, Camille, Bidet, Audrey, Delabesse, Eric, Rieu, Jean Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, Sarry, Audrey, Rey, Héloïse, de Grande, Anne-Charlotte, Despas, Fabien, Pigneux, Arnaud, Récher, Christian
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448603/
https://ncbi.nlm.nih.gov/pubmed/32790847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002511
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars